Bipolar: Physical activity may boost mood and energy

Ana sandoiu | December 29, 2018

article image
New research, published in the journal JAMA Psychiatry, found that higher levels of physical activity boost mood and energy levels. The benefits were particularly noticeable in people with bipolar disorder. In the United States, almost 3 percent of adults experienced bipolar disorder "in the past year." Around 4.4 percent of adults have bipolar at some point in their lives.

Spotlight

Ferrosan Medical Devices A/S

Ferrosan Medical Devices provides a range of innovative medical devices. Our focus is centered on haemostasis during surgery, regional anaesthesia and biopsy. Ferrosan Medical Devices consists of two entities: Biomaterials & Electromechanics. Biomaterials develops and manufactures advanced topical haemostatic products to control bleeding in surgery. The products are marketed in more than 100 countries around the globe via Ethicon Biosurgery, a Johnson & Johnson Company. In addition, selected countries and segments are served by Takeda, Sanofi-Aventis and Elanco Animal Health.

OTHER ARTICLES

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | March 6, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

Ferrosan Medical Devices A/S

Ferrosan Medical Devices provides a range of innovative medical devices. Our focus is centered on haemostasis during surgery, regional anaesthesia and biopsy. Ferrosan Medical Devices consists of two entities: Biomaterials & Electromechanics. Biomaterials develops and manufactures advanced topical haemostatic products to control bleeding in surgery. The products are marketed in more than 100 countries around the globe via Ethicon Biosurgery, a Johnson & Johnson Company. In addition, selected countries and segments are served by Takeda, Sanofi-Aventis and Elanco Animal Health.

Events